Cargando…
Triple combination therapy for clinically nonmetastatic super‐high‐risk prostate cancer
INTRODUCTION: Patients with nonmetastatic but exceptionally high‐risk prostate cancer are liable to have biochemical failure and may even die. Triple combination therapy, which consists of surgery, radiotherapy, and androgen‐deprivation therapy, as first‐line treatment, may control the disease for a...
Autores principales: | Yoshimura, Koji, Muraoka, Kei, Fukasawa, Michiko, Fukushima, Mika, Kumagai, Masatoshi, Yabusaki, Ryo, Ueda, Masakatsu, Shiraishi, Yusuke, Imamura, Masaaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249652/ https://www.ncbi.nlm.nih.gov/pubmed/35795109 http://dx.doi.org/10.1002/iju5.12457 |
Ejemplares similares
-
Prostate cancer recurring as small‐cell carcinoma with a
BRCA2
somatic mutation
por: Yabusaki, Ryo, et al.
Publicado: (2022) -
Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014) -
Significance of delayed primary excision in localized nonmetastatic adult head and neck rhabdomyosarcoma
por: Kobayashi, Kenya, et al.
Publicado: (2016) -
Image quality improvement in cone-beam CT using the super-resolution technique
por: Oyama, Asuka, et al.
Publicado: (2018) -
Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)